Regeneron Pharmaceuticals Inc. buy Citigroup Inc.
Summary
This prediction is currently active. The BUY prediction by Citigroup_Inc_ for Regeneron Pharmaceuticals Inc. has seen massive gains of 40.67%. Dividends of €0.88 are taken into consideration when calculating the performance. This prediction currently runs until 13.10.26. The prediction end date can be changed by Citigroup_Inc_ at any time. Citigroup_Inc_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 2.530% | 2.530% |
| iShares Core DAX® | 2.705% | -1.771% |
| iShares Nasdaq 100 | 4.127% | -1.874% |
| iShares Nikkei 225® | 1.944% | -3.187% |
| iShares S&P 500 | 2.919% | -0.149% |
Comments by Citigroup_Inc_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Citigroup_Inc_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
29.10.25
29.10.26
28.11.25
Regeneron Pharmaceuticals Inc.
02.06.25
02.06.26
28.11.25
Regeneron Pharmaceuticals Inc.
14.05.25
14.05.26
28.11.25

